Where to Buy Melanotan II

Structural and Mechanistic Differences: Why These Matter

Melanotan I (MT-I, Afamelanotide) is a linear 13-amino acid peptide analog of alpha-melanocyte stimulating hormone (α-MSH). Melanotan II is a cyclic structure (formed by disulfide bond between cysteine residues) of a similar peptide backbone. This structural difference fundamentally changes receptor selectivity and potency.

MT-I has high selectivity for melanocortin 1 (MC1) receptors—the subtype primarily responsible for skin pigmentation. It produces minimal activation of MC3, MC4, and MC5 receptors that mediate appetite, sexual function, and stress responses. This selectivity makes MT-I mechanistically "cleaner"—targeting pigmentation with less collateral activation of other systems.

MT-II's cyclic structure and amino acid composition increase affinity for non-selective melanocortin receptor activation. It binds strongly to MC1 (pigmentation), but also robustly activates MC3 (sexual function), MC4 (appetite suppression, energy expenditure), and MC5 (sebaceous gland activity). This polyvalent activation enables potent, rapid tanning but creates multisystem side effects MT-I avoids.

Pigmentation Speed and Intensity: MT-II Wins, But At What Cost?

MT-I produces visible pigmentation changes over 7-14 days with continued darkening over 4-8 weeks. The tan is gradual, mimicking natural sun-induced darkening. Peak pigmentation occurs around week 8-12 of MT-I use. Skin darkening is even and controlled; users report the ability to achieve pale or deep tans by modulating dose.

MT-II produces visible pigmentation within 2-3 days of first injection, with dramatic darkening by day 5-7. The pigmentation change is rapid and intense. This speed comes from non-selective melanocortin activation—MT-II essentially floods the system with pigmentation signals rather than gently nudging them like MT-I does. For users seeking rapid aesthetic results, MT-II clearly wins on speed. For users prioritizing safety and natural appearance, MT-I's gradual approach is preferable.

Systemic Side Effects: MT-I vs. MT-II Safety Profiles

Nausea: MT-I causes minimal nausea in 5-10% of users at recommended doses; when present, it's mild and transient (15-30 minutes). MT-II causes severe nausea in 30-50% of users, often lasting 2-4 hours post-injection and accompanied by vomiting in 20-30% of cases. Clear advantage: MT-I.

Appetite Suppression: MT-I produces no meaningful appetite suppression at standard doses. Users maintain normal hunger signals and food intake. MT-II causes pronounced appetite suppression in most users—complete anorexia (inability to eat) in some, lasting 6-12 hours post-injection. For users trying to maintain or gain weight, MT-II becomes problematic. Advantage: MT-I.

Involuntary Erections and Sexual Dysfunction: MT-I at recommended doses produces no spontaneous erections or sexual dysfunction. Sexual function remains normal. MT-II causes involuntary, sometimes painful erections in 40-60% of male users, lasting 2-4 hours and unrelated to sexual stimulus. Some users experience priapism (pathological erection lasting >4 hours). Female users report clitoral stimulation and sexual arousal unrelated to sexual context. Clear advantage: MT-I.

Vasodilation and Facial Flushing: MT-I may produce mild facial warmth in sensitive individuals, but true flushing is uncommon. MT-II causes pronounced facial flushing (redness, warmth) in most users, often severe enough to cause social embarrassment. Advantage: MT-I.

Yawning and Excessive Salivation: MT-I: minimal yawning, no salivation issues. MT-II: excessive yawning in some users (clusters of 10-20 yawns over 30 minutes), some reports of excessive salivation. Advantage: MT-I.

Serious Systemic Toxicity: MT-II's Documented Hazards

MT-I: No documented cases of rhabdomyolysis, renal infarction, or posterior reversible encephalopathy syndrome (PRES) in the literature. Even high-dose MT-I studies show good safety profiles. Cardiovascular complications are rare even in users with underlying hypertension.

MT-II: Well-documented cases of rhabdomyolysis (muscle breakdown) with associated acute kidney injury requiring hospitalization and sometimes dialysis. Cases of renal infarction (kidney tissue necrosis) causing permanent renal function loss. Documented cases of PRES (life-threatening cerebral edema and hypertension) in young users without prior neurologic disease. Severe hypertension (systolic >180) in 20-30% of users. These serious complications are MT-II-specific; they don't occur with MT-I at any dose.

This difference is mechanistically meaningful: MC4 activation (unique to MT-II) triggers sympathomimetic stress, hemoconcentration, and rhabdomyolysis risk. MT-I's selectivity for MC1 avoids these pathways entirely, explaining the superior safety profile.

Dosing and Duration: Different Protocols for Different Goals

MT-I Dosing: Typically 10 mg per dose, 1-2 times weekly, cycles of 8-12 weeks. Some users taper to 5 mg weekly for maintenance tanning. Frequent dosing is unnecessary because MT-I produces cumulative pigmentation lasting weeks post-discontinuation. Longer cycles (12+ weeks) are safe based on clinical data.

MT-II Dosing: Loading dose 500-1000 mcg, then maintenance 250-500 mcg every 48 hours for 2-4 weeks. Longer cycles (8+ weeks) increase cumulative toxicity risk. Most safety-conscious users limit MT-II cycles to 3-4 weeks maximum due to side effect and serious complication concerns.

MT-I's larger per-dose amount (10 mg) reflects its lower potency per molecule; MT-II's smaller doses (250-500 mcg) reflect its higher potency and non-selective activity. Despite smaller doses, MT-II produces disproportionately more systemic effects due to receptor selectivity differences.

Cost Comparison and Value Proposition

MT-I: Typically $100-200 per 10 mg vial. A standard 12-week cycle requires 6-12 vials (depending on frequency), totaling $600-2400 for a complete cycle. High cost reflects clinical research background and pharmaceutical-grade manufacturing standards.

MT-II: Typically $35-60 per 10 mg vial. A 4-week cycle requires 2-4 vials, totaling $70-240. Much lower cost, but shorter duration and higher risk profile. Cost-per-result is actually comparable: MT-II's cheaper price is offset by more limited duration and potential serious complications requiring medical intervention.

From a value-for-money perspective considering total safety profile, MT-I may actually be cheaper long-term despite higher per-vial cost, since you don't risk hospitalization from rhabdomyolysis or renal infarction.

Melanoma and Atypical Mole Risk: Comparative Assessment

MT-I: Afamelanotide (the approved pharmaceutical form of MT-I) is used clinically in some countries for photosensitivity disorders. Clinical experience with high-dose, long-term MT-I hasn't revealed increased melanoma incidence beyond background rates. Animal studies show good safety at high doses.

MT-II: No clinical approval or long-term human safety data. Mechanism (forcing rapid melanocyte activation without natural photoprotective feedback) theoretically increases malignant transformation risk. Case reports of users developing multiple atypical moles and melanoma during/shortly after MT-II cycles are anecdotally common, though causality cannot be definitively proven without prospective studies.

MT-I's selectivity for MC1 and established safety data suggest lower melanoma risk. MT-II's non-selective mechanism and lack of long-term human safety data create genuine uncertainty—potentially higher melanoma risk that can't be quantified.

Legal and Regulatory Status: Why MT-I Has Better Standing

MT-I (Afamelanotide, brand name Scenesse) is FDA-approved for erythropoietic protoporphyria (a photosensitivity disorder). It's available by prescription in limited jurisdictions. This regulatory history reflects clinical trials demonstrating safety and efficacy. While prescription MT-I is not available for tanning in most countries, its FDA approval gives it legitimacy and some assurance of quality if sourcing the approved pharmaceutical.

MT-II has never passed FDA approval or clinical trials for human use. It remains a research chemical with minimal regulatory oversight. This distinction is important: approved drugs have manufacturing quality standards, batch testing requirements, and adverse event reporting mechanisms. Research chemicals like MT-II sold as "for research only" bypass all these safeguards.

User Experience and Tolerability: Which Is Easier to Use?

MT-I users report minimal side effects, maintaining normal daily function. Dosing is once-twice weekly, so injection frequency is low. The gradual tan allows natural integration into appearance. Social disruption from involuntary erections, appetite suppression, or uncontrollable yawning is nonexistent.

MT-II users often report significant quality-of-life disruption during use: nausea requiring time off work, inability to eat normally (problematic if trying to gain muscle), involuntary erections (socially embarrassing), and general sympathomimetic malaise (anxiety, tremor, agitation). The rapid tan is striking, but comes with substantial short-term tolerability costs.

From a "ease of use" perspective, MT-I is clearly superior for someone trying to maintain normal function while tanning. MT-II requires accepting substantial acute side effects for the benefit of faster results.

Which Is Right for You? Decision Framework

Choose MT-I if: You prioritize safety and don't mind gradual tanning. You want minimal side effects during use. You plan extended use (8+ weeks). You're concerned about serious systemic complications. You value regulatory legitimacy and pharmaceutical-grade sourcing.

Choose MT-II if: You need rapid tanning (days/weeks, not months). You can tolerate acute side effects (nausea, appetite suppression, involuntary erections). You plan short cycles (2-4 weeks). You're willing to accept uncertainty about long-term melanoma risk. You prioritize speed over safety margins.

For most users, MT-I's superior safety profile, lack of serious documented complications, and regulatory history make it the better choice despite higher cost and slower results. MT-II is appropriate only for users accepting documented risks for accelerated results.

Frequently Asked Questions

Is Melanotan I safer than Melanotan II?

Yes. MT-I has selective MC1 activity, documented clinical use, and excellent safety profile without serious complications. MT-II has non-selective activity, documented rhabdomyolysis and renal complications, and unknown long-term safety. MT-I is substantially safer.

Why is Melanotan II more popular if MT-I is safer?

Speed and cost. MT-II produces visible results within days; MT-I takes weeks. MT-II costs $35-60 per cycle; MT-I costs $600-2400. Users prioritizing fast, cheap tanning choose MT-II despite safety concerns. Users prioritizing safety choose MT-I.

Can I get Melanotan I prescribed?

In some countries (UK, Sweden, others) afamelanotide is available by prescription for photosensitivity disorders. Obtaining it for tanning specifically is difficult or impossible. Most users sourcing MT-I do so through research peptide suppliers (same category as MT-II), though some MT-I available this way comes from pharmaceutical-grade manufacturing.

Does Melanotan I cause involuntary erections like Melanotan II?

No. MT-I's MC1 selectivity means it doesn't activate MC3/MC4 pathways that cause erections. Users report normal sexual function throughout MT-I use. This is one of the clearest safety advantages of MT-I over MT-II.

Which causes more melanoma risk, MT-I or MT-II?

Unknown definitively. MT-I's clinical track record suggests low risk. MT-II's mechanism (rapid, non-selective melanocyte activation) theoretically increases risk, and anecdotal reports of atypical moles/melanoma during/after MT-II cycles are common. MT-I appears safer based on available evidence.

Should I choose Melanotan I or II as a beginner?

If you're new to melanotans, start with MT-I. Its safety profile is better understood, side effects are minimal, and you can assess your tolerance to the compound without serious systemic risks. MT-II can be explored later if you understand and accept the documented hazards.